Allegheny Health Network

Running trials

• Recruiting

  HeartBeam ECG Registry

  NCT07501299· HeartBeam, Inc.· Source

• Recruiting

  Anastomotic Safety and Surveillance Using Real-time Enhanced Sensing Using xBar

  NCT07337590· Exero Medical Ltd.· Source

• Recruiting

  A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  NCT07184944· Phase 3· Sanofi· Source

• Recruiting

  A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07185009· Phase 3· Sanofi· Source

• Recruiting

  A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  NCT07188558· Phase 3· Lyell Immunopharma, Inc.· Source

• Recruiting

  Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

  NCT07195591· Phase 3· GT Medical Technologies, Inc.· Source

• Recruiting

  An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07184996· Phase 3· Sanofi· Source

• Recruiting

  An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  NCT07184931· Phase 3· Sanofi· Source

• Active, not recruiting

  Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)

  NCT07120945· Medtronic - MITG· Source

• Recruiting

  A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

  NCT06971614· Phase 2· ImmVira Pharma Co. Ltd· Source

• Enrolling by invitation

  Utility of Random Biopsies in Patients With Inflammatory Bowel Disease

  NCT06560021· Abramson Cancer Center at Penn Medicine· Source

• Active, not recruiting

  A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

  NCT06095128· Phase 4· Takeda· Source

• Recruiting

  AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

  NCT06063850· Phase 1/2· UniQure Biopharma B.V.· Source

• Active, not recruiting

  Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

  NCT06211036· Phase 3· Amgen· Source

• Recruiting

  A Registry for People With Lung Cancer

  NCT06424327· Memorial Sloan Kettering Cancer Center· Source

• Active, not recruiting

  A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

  NCT06045754· Phase 4· Takeda· Source

• Active, not recruiting

  Real-world Safety and Effectiveness Registry of Catheter Ablation of Paroxysmal Atrial Fibrillation as Initial Control Therapy With the Thermocool SmartTouch SF Catheter (A Sub-study of REAL AF Registry)

  NCT07092774· Heart Rhythm Clinical and Research Solutions, LLC· Source

• Recruiting

  A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

  NCT06072781· Phase 3· Verastem, Inc.· Source

• Recruiting

  Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  NCT06128551· Phase 1/2· Revolution Medicines, Inc.· Source

• Recruiting

  MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach

  NCT06050707· Phase 2· University Health Network, Toronto· Source

• Recruiting

  A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

  NCT06057935· Phase 2· Memorial Sloan Kettering Cancer Center· Source

• Recruiting

  Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

  NCT05727904· Phase 3· Iovance Biotherapeutics, Inc.· Source

• Recruiting

  Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  NCT05579366· Phase 1/2· Genmab· Source

• Recruiting

  A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

  NCT05552222· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Study of INCB123667 in Subjects With Advanced Solid Tumors

  NCT05238922· Phase 1· Incyte Corporation· Source

• Active, not recruiting

  CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung

  NCT05306288· Delfi Diagnostics Inc.· Source

• Active, not recruiting

  Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

  NCT05081193· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Recruiting

  A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  NCT04988555· Phase 1/2· Sumitomo Pharma America, Inc.· Source

• Recruiting

  Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

  NCT04998669· Phase 2· Juan P. Alderuccio, MD· Source

• Recruiting

  RA-PRO PRAGMATIC TRIAL

  NCT04692493· Phase 3· University of Alabama at Birmingham· Source

• Recruiting

  JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

  NCT05064540· Endologix· Source

• Active, not recruiting

  Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT04781088· Phase 2· Floor Backes, MD· Source

• Recruiting

  Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  NCT04606914· Phase 2· University of Alabama at Birmingham· Source

• Active, not recruiting

  Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)

  NCT04365374· Phase 3· GT Medical Technologies, Inc.· Source

• Active, not recruiting

  An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

  NCT04717414· Phase 3· Celgene· Source

• Recruiting

  Parkinson's Foundation PD GENEration Genetic Registry

  NCT04994015· Parkinson's Foundation· Source

• Recruiting

  Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

  NCT04427384· GT Medical Technologies, Inc.· Source

• Active, not recruiting

  Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

  NCT04142437· Bayer· Source

• Recruiting

  Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

  NCT04045665· Phase 3· Icahn School of Medicine at Mount Sinai· Source

• Active, not recruiting

  Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

  NCT04146051· Phase 2· Cartesian Therapeutics· Source

• Recruiting

  The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

  NCT04075305· UMC Utrecht· Source

• Active, not recruiting

  9-ING-41 in Patients With Advanced Cancers

  NCT03678883· Phase 2· Actuate Therapeutics Inc.· Source

• Recruiting

  The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

  NCT03142152· Cardiac Dimensions, Inc.· Source

• Recruiting

  Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias

  NCT04088071· Heart Rhythm Clinical and Research Solutions, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer5 recruiting
• Ovarian cancer4 recruiting
• Colorectal cancer3 recruiting
• Crohn's disease3 recruiting
• Ulcerative colitis3 recruiting
• Atrial fibrillation2 recruiting
• Bladder cancer2 recruiting
• Childhood cancers2 recruiting
• Endometrial cancer2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Glioblastoma2 recruiting
• Mesothelioma2 recruiting
• Multiple myeloma2 recruiting
• Pancreatic cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• Aortic aneurysm1 recruiting
• Brain metastases1 recruiting
• Cervical cancer1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Epilepsy1 recruiting
• Follicular lymphoma1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Meningioma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Parkinson disease1 recruiting
• Prostate cancer1 recruiting
• Rheumatoid arthritis1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  AIMIGo 12L ECG Synthesis Software Pivotal Study for Arrythmia Detection

  NCT06123130· HeartBeam, Inc.· Source

• Completed

  Determining the Validity of ThinkSono Guidance for Ultrasound Image Acquisition and Remote Detection

  NCT06652568· ThinkSono, Ltd.· Source

• Recruiting

  A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

  NCT06022029· Phase 1· OncoNano Medicine, Inc.· Source

• Completed

  Re-Ablation Using a Tailored Approach Targeting EGM-Dispersion

  NCT05477147· Volta Medical· Source

• Completed

  A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA

  NCT05601128· Phase 3· Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)· Source

• Completed

  A Clinical Utility Study of PrismRA for Rheumatoid Arthritis

  NCT05161234· Scipher Medicine· Source

• Completed

  DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

  NCT04825834· Delfi Diagnostics Inc.· Source

• Completed

  Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

  NCT04751487· Phase 3· Sanofi· Source

• Terminated

  Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

  NCT04203160· Phase 1/2· University of Michigan Rogel Cancer Center· Source

• Completed

  Registry of Asthma Patients Initiating DUPIXENT®

  NCT04287621· Regeneron Pharmaceuticals· Source

• Completed

  Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

  NCT04210115· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease

  NCT03622905· Functional Neuromodulation Ltd· Source

• Completed

  Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma

  NCT03632135· Phase 3· Cordgenics, LLC· Source

• Completed

  Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

  NCT02910557· Amgen· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Endometrial cancer17 works · 4 trials
• Brain metastases14 works · 2 trials
• Gastroparesis9 works · 0 trials
• Barrett's oesophagus7 works · 0 trials